Edition:
India

Sophiris Bio Inc (SPHS.OQ)

SPHS.OQ on NASDAQ Stock Exchange Capital Market

3.77USD
22 Jun 2018
Change (% chg)

$-0.04 (-1.05%)
Prev Close
$3.81
Open
$3.83
Day's High
$3.83
Day's Low
$3.73
Volume
9,402
Avg. Vol
43,340
52-wk High
$4.04
52-wk Low
$1.80

Chart for

About

Sophiris Bio Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing products for the treatment of urological diseases. The Company is developing topsalysin (PRX302) as a treatment for the lower urinary tract symptoms of benign prostatic hyperplasia (BPH) commonly referred to as an enlarged... (more)

Overall

Beta: 2.10
Market Cap(Mil.): $70.63
Shares Outstanding(Mil.): 30.11
Dividend: --
Yield (%): --

Financials

  SPHS.OQ Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -0.26 -- --
ROI: -47.03 14.84 14.38
ROE: -97.97 16.34 16.08

BRIEF-Sophiris Bio Q4 Loss Per Share $0.13

* SOPHIRIS BIO REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND KEY CORPORATE HIGHLIGHTS

22 Mar 2018

Competitors

  Price Chg
Astellas Pharma Inc (4503.T) ¥1,758 +2.00
Pfizer Inc. (PFE.N) $36.44 +0.14
Merck & Co., Inc. (MRK.N) $61.53 +0.35
Sanofi SA (SASY.PA) €68.72 +1.01
GlaxoSmithKline plc (GSK.L) 1,543.40 +5.00
Eli Lilly And Co (LLY.N) $86.05 -0.02

Earnings vs. Estimates